.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a mean consequence of 11 months, clients along with metastatic intestinal growths that obtained biomarker-matched treatments based on distributing tumor DNA profiling showed a greater clinical perk than those acquiring incomparable treatment.